Pair Name	Gossypol, Ponatinib
Disease Info	[ICD-11: 2A00-2F9Z]	Solid tumour or cancer		Investigative
Biological Phenomena	Inhibition-->Angiogenesis
Gene Regulation	Up-regulation	Expression	TP53	hsa7157
	Up-regulation	Expression	CASP9	hsa842
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	VEGFA	hsa7422
	Down-regulation	Expression	FGFR4	hsa2264
In Vivo Model	EAC cells were maintained through serial intraperitoneal inoculation of saline solution containing 106 cells/mouse into female Swiss albino mice (El-Wahab and Fouda, 2009). After 10 days, the host mice were euthanized by cervical dislocation, and the cells were recovered by collecting them using a syringe, washing them in normal saline, and counting them.
Result	Gossypol could be used as an adjuvant medication for ponatinib in cancer treatment, possibly leading to successful dose reductions and fewer side effects; however, further research is needed before a clinical application could be feasible.